|
Background: bronchial asthma (bronchial asthma, asthma) is a common and serious global health problem, this chronic airway disease can be accumulated in different countries, different regions and ethnic people of different age groups, in serious cases can cause death. Complex pathogenesis of bronchial asthma is currently no cure. Heavier disease burden worldwide, effective asthma control depends on the joint efforts that both doctors and patients. Inhalation treatment of bronchial asthma is the treatment of choice of the Global Initiative for Asthma (GINA), has received extensive attention in clinical medical workers. Inhalation therapy is to act quickly, side effects, and easy to use, less medication, and other advantages, to become the preferred method of treatment of bronchial asthma. The pathological changes in bronchial asthma is airway inflammation and airway smooth muscle spasm, inflammation plays an important role in which, With the establishment of the mechanism of inflammation of the bronchial asthma, asthma treatment goals by controlling acute attack into the prevention and treatment of chronic airway inflammation eventually eliminate the symptoms of asthma. Therefore, in the late 1950s began to study the the inhaled glucocorticoid hormone (ICS). Budesonide is inhaled anti-inflammatory glucocorticoid which a higher affinity for the glucocorticoid receptor. By inhibiting aggregation and activation of inflammatory cells, epithelial cell hyperplasia and injury and thickening of the basement membrane, reducing the formation of vascular permeability and angiogenesis, and reversal the airway hyperresponsiveness performance remission the Sufa and delayed allergic reaction induced airway inflammation and bronchial obstruction; inhibit the release of inflammatory mediators and cytokine-mediated immune response, so as to achieve the anti-allergic inflammation and anti-inflammatory effects. In long-acting β2 body as a new type of highly selective agonist formoterol, a major role in the smooth muscle cells in the β2 receptor to relieve bronchospasm. But also has a strong anti-inflammatory activity, it is possible to suppress the infiltration of inflammatory cells in the airway vascular permeability and antigen-induced airway. These two types of mechanism of drug action and the role of target different combination good complementary role. Clinical applications alone ICS program for the poor efficacy of moderate persistent asthma patients. Composite formulation of budesonide and formoterol, due to the different segments of the role of inflammation in asthma, can be effective in reducing asthma symptoms, improve quality of life, improve lung function, reduce airway hyperresponsiveness to control airway inflammation, reduce asthma attack frequency and mitigate the severity of the attack, to reduce mortality and improve patient compliance. The rapid onset of action, and significantly improved lung function, more effective than the single high-dose inhaled Couverture hormone also reduces the rate of worsening symptoms. Broader prospects for clinical applications. Objective: To explore budesonide and formoterol inhalation treatment of bronchial asthma patients, IL-17, IL-33, interferon-gamma and lung function, and further open up new avenues for the treatment of bronchial asthma. Method: to meet the conditions of 40 patients with bronchial asthma in patients with acute exacerbation were randomly divided into two groups, conventional group and treatment group 20 cases each. The conventional conventional treatment group using antibiotics, hormones, Doxofylline; given 2 times a, 4.5μg day, formoterol, budesonide 160μg inhaled treatment group on the basis of conventional therapy. Regimens for 2 weeks. Was measured before and after treatment in patients with IL-17, IL-33, gamma interferon and lung function, in contrast to the indicators to improve the presence or absence of significant difference in the two groups of patients before and after treatment, and the evaluation of the two methods in the treatment of bronchial asthma in clinical efficacy. Results: 1, bronchial asthma, acute exacerbation of the patient's body IL-17 level was significantly higher in the treatment group and conventional group above factors were decreased (P lt; 0.05), the treatment group than in the conventional group decreased more significantly, there was significant difference significance (P lt; 0.05). , Acute bronchial asthma attack in patients in vivo IL-33 levels were significantly increased in the treatment group and conventional group the above factors were decreased (P lt; 0.05), the treatment group than in the conventional group decreased more significantly, the difference was significant significance (P lt; 0.01). 3, acute bronchial asthma attack in patients in vivo INF-γ levels was significantly higher in the treatment group and conventional group The above factor levels had no significant change (P gt; 0.05). 4, in patients with bronchial asthma acute exacerbation was obstructive ventilatory dysfunction, so the PEF, FEV1/FVC% decreased. After treatment PEF, FEV1/FVC% were significantly increased (P lt; 0.01). Treatment group than in the conventional group increased significantly (P lt; 0.01). Conclusion: 1, bronchial asthma patients with acute exacerbation of IL-17, IL-33 levels were higher than normal levels, this result is consistent with our expected results, INF-γ levels higher than normal levels after budesonide and Fu Mote Luo United inhalation treatment of IL-17, IL-33 levels than before declined (P lt; 0.05), compared with the previous level of INF-γ no significant change (P gt; 0.05). Acute exacerbation of bronchial asthma, lung function was obstructive ventilatory dysfunction, budesonide and formoterol inhalation after treatment can be effective in improving lung ventilation function to strengthen the air to flow freely. Budesonide and formoterol inhalation treatment joint coordinating role, can improve the immune function of patients with asthma.
|